Why is Cardinal Health stock surging today?
Cardinal Health (CAH) shares rose about 3.3% pre-open after the company reported fiscal Q4 2026 results above Wall Street expectations. Non-GAAP diluted EPS was $2.91 vs $2.42 consensus, with revenue of $63.7B. For FY2026, non-GAAP EPS was $11.26 and operating cash flow $5.2B. FY2027 guidance was $12.40–$12.60 and it authorized a $5.0B buyback plus a $0.5158 dividend.
How this was made
The 30-second read
Why it matters
For traders, the key decision inputs are the explicit 2027 non-GAAP EPS guidance range and the new $5.0B share repurchase authorization, which can change near-term expectations for earnings growth and buyback support.
Market read
A same-day earnings and guidance catalyst with a sizable buyback authorization is a direct repricing event for CAH.
What to watch
The article does not quantify margin drivers or any guidance risks, so traders may be underestimating execution or cost pressures behind the margin expansion narrative.
Background
The piece frames Cardinal Health’s pre-open surge as a response to a fiscal Q4 earnings beat, full-year strength, and shareholder-friendly capital return.
Ticker impact
Cardinal Health shares rose pre-open after fiscal Q4 2026 results beat estimates, with non-GAAP EPS $2.91 vs $2.42 consensus.
Bullish bias for the next several sessions as traders reprice growth and capital-return expectations.
The article cites specific EPS/revenue beats, explicit 2027 non-GAAP EPS guidance ($12.40–$12.60), and a $5.0B incremental repurchase authorization, all of which are direct drivers of valuation and sentiment.
Market effects
A strong distributor earnings and guidance print can lift sentiment across healthcare distribution and related supply-chain names.
Primarily US large-cap sentiment, with limited direct regional spillover beyond healthcare equities.
Modest global relevance, mainly through US healthcare distribution demand and capital-return signaling.
Counterpoint
The stock is already near prior 52-week highs, so the move may be vulnerable to profit-taking even after a good print.
Key entities
- companyCardinal Health
Subject of the article, reporting fiscal Q4 2026 results, issuing fiscal 2027 guidance, and announcing a new $5.0B share repurchase authorization.
